Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint ...
Pharmabiz7h
Valneva submits label extension application for Ixchiq with UK MHRA to expand its use to adolescents aged 12 to 17 years in EU
Saint Herblain, France Tuesday, April 1, 2025, 16:00 Hrs [IST] ...
Valneva (NASDAQ:VALN) Receives “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Valneva (NASDAQ:VALN – Free Report) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $17.00 ...